Sign up for Table of Contents Alerts.
Email this page
Print this page
Research Paper
Fluorescently Labeled Cetuximab to Evaluate Head and Neck Cancer Response to Treatment
John P. Gleysteen, Ryan D. Duncan, J. Scott Magnuson, Joni B. Skipper, Kurt Zinn and Eben L. Rosenthal
volume 6 | issue 8
August 2007Pages: 1181 - 1185
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Objective: Combining the therapeutic and diagnostic properties of targeted antibodies may improve clinical assessment of disease with limited added toxicity during treatment. Methods: Mice (n=10) were xenografted with SCC-1 tumor cells and then treated with radiation, cisplatin, and cetuximab. Brightfield and fluorescent imaging was performed after systemically injecting fluorescently labeled cetuximab prior to treatment and at 6 or 10 weeks after initiation of treatment. The relative fluorescence intensity was determined for each image. Results: The tumor luminosity measured before (week 0), during (week 6) and after treatment (week 10) did not significantly change. Actual tumor measurement corresponded to fluorescent measurements of tumors both before treatment and after treatment. Complete response to therapy occurred in one animal, where resolution of the tumor correlated with loss of fluorescent activity. Conclusions: This preclinical data suggests combining the diagnostic and therapeutic properties of cetuximab may be clinically useful.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.